Results 141 to 150 of about 2,811,792 (409)

Drugs induced Raynaud's phenomenon and underlying mechanism: a disproportionality analysis from the WHO pharmacovigilance database

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's Phenomenon (RP) and to explore their potential pathophysiological mechanisms through a mixed disproportionality/clustering analysis from the WHO pharmacovigilance database.
Alex Hlavaty   +4 more
wiley   +1 more source

Loss of angiotensin II receptor expression in dopamine neurons in Parkinson’s disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activation [PDF]

open access: yes, 2015
In rodent models of Parkinsons disease (PD), dopamine neuron loss is accompanied by increased expression of angiotensin II (AngII), its type 1 receptor (AT1), and NADPH oxidase (Nox) in the nigral dopamine neurons and microglia.
Aboud, O   +6 more
core   +2 more sources

Suppression of Resting Metabolism by the Angiotensin AT2 Receptor [PDF]

open access: gold, 2016
Nicole K. Littlejohn   +16 more
openalex   +1 more source

Angiotensin receptor blockers and risk of dementia: cohort study in UK Clinical Practice Research Datalink

open access: yesBritish Journal of Clinical Pharmacology, 2015
Aims This was a cohort study to evaluate whether individuals exposed to angiotensin receptor blockers have a reduced risk of dementia compared with those exposed to angiotensin-converting enzyme inhibitors.
K. L. Goh   +5 more
semanticscholar   +1 more source

Molecular stratification of antiphospholipid syndrome through integrative analysis of the whole‐blood RNA transcriptome

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Antiphospholipid syndrome (APS) is a thrombo‐inflammatory disorder characterized by clinical and mechanistic heterogeneity that complicates early diagnosis and hinders targeted treatment. We aimed to identify distinct molecular endotypes among antiphospholipid antibody (aPL)‐positive patients using whole‐blood transcriptomics.
Amala Ambati   +13 more
wiley   +1 more source

Особенности использования антигипертензивных препаратов у больных сахарным диабетом [PDF]

open access: yes, 2004
In this article the modern data about pharmaceuticals drugs that used for treatment of patients with arterial hypertension and diabetes mellitus are submitted.
Rachynskyi, Ivan Danylovych   +3 more
core  

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study [PDF]

open access: yes, 2018
Aims: To test the prognostic value of emerging biomarkers in the Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) trial. Methods and results: Circulating cardiac [N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high ...
Alehagen   +34 more
core   +4 more sources

Beyond right or wrong: How partial credit scoring on multiple‐choice questions improves student performance and assessment perceptions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims In this study, we examined the effects of assigning partial credit to selected answer choices on student performance and perceptions in a pharmacology course using Type A multiple‐choice questions (MCQs). Methods Partial credit scoring was incorporated into quizzes and exams in a 10‐week pharmacology course for postbaccalaureate premedical ...
Stephen D. Schneid   +2 more
wiley   +1 more source

Assessment and Management of Hypertension among Patients on Peritoneal Dialysis [PDF]

open access: yes, 2019
Approximately 7%-10% of patients with ESKD worldwide undergo peritoneal dialysis (PD) as kidney replacement therapy. The continuous nature of this dialytic modality and the absence of acute shifts in pressure and volume parameters is an important ...
Agarwal, Rajiv   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy